Belite Bio Completes NDA Submission for Tinlarebant as Potential First Treatment for Stargardt Disease

Belite Bio Reaches Important Regulatory Milestone

Belite Bio has announced the completion of its rolling New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for tinlarebant, an investigational oral therapy being developed for Stargardt disease type 1 (STGD1).

The company began the rolling NDA submission process in April 2026 under the FDA’s Breakthrough Therapy Designation pathway. With the final portion of the application now submitted, the FDA will begin its standard 60-day review process to determine whether the application will be accepted for filing. If accepted, the agency will assign a Prescription Drug User Fee Act (PDUFA) target action date.

The milestone brings tinlarebant one step closer to potentially becoming the first approved treatment for Stargardt disease, a rare inherited retinal disorder that currently has no approved therapies.

A Rare Eye Disease With No Approved Treatment

Stargardt disease type 1 is a genetic retinal disorder caused by mutations in the ABCA4 gene. The condition gradually damages the retina and leads to progressive and irreversible vision loss.

The disease often begins at a young age and can significantly affect daily activities, education, and independence as vision continues to decline over time.

According to Belite Bio, Stargardt disease affects an estimated 53,000 people in the United States alone. Despite the burden of the disease, patients currently have no FDA-approved treatment options available.

Tinlarebant Aims to Slow Disease Progression

Tinlarebant is a once-daily oral therapy designed to reduce the buildup of harmful vitamin A-based toxins known as bisretinoids in the retina.

These toxic compounds are generated as by-products of the visual cycle and are believed to play a major role in retinal degeneration in Stargardt disease. They are also associated with disease progression in geographic atrophy, an advanced form of dry age-related macular degeneration (AMD).

The therapy works by lowering levels of retinol binding protein 4 (RBP4), which is responsible for transporting vitamin A from the liver to the eye. By reducing the amount of vitamin A reaching the retina, tinlarebant aims to decrease the formation of toxic bisretinoid compounds.

Researchers believe this approach may help slow retinal damage and preserve vision for a longer period.

Phase 3 DRAGON Study Supports NDA Filing

The NDA submission is supported by positive results from the Phase 3 DRAGON clinical trial.

According to the company, the study met its primary endpoint and demonstrated that tinlarebant significantly reduced the growth rate of retinal lesions compared with placebo.

These findings suggest that the therapy may help slow disease progression in patients with Stargardt disease.

Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio, stated that the Phase 3 data highlight the potential of tinlarebant to become the first approved treatment option for patients living with this vision-threatening condition.

Breakthrough Therapy Designation Helped Accelerate Development

The FDA previously granted Breakthrough Therapy Designation to tinlarebant because of the significant unmet medical need in Stargardt disease.

In addition to Breakthrough Therapy Designation, the therapy has received several other regulatory recognitions, including:

• Fast Track Designation in the United States.
• Rare Pediatric Disease Designation in the United States.
• Orphan Drug Designation in the United States, Europe, Japan, and Switzerland.
• Sakigake Designation in Japan.

These designations are intended to support and accelerate the development of treatments for serious or rare diseases with limited therapeutic options.

Belite Bio Preparing for Potential Commercial Launch

Belite Bio stated that it is continuing commercial readiness activities while awaiting feedback from the FDA.

Dr. Tom Lin, Chairman and Chief Executive Officer of Belite Bio, described the completion of the NDA submission as an important achievement for both the company and the Stargardt disease community. He also acknowledged the contributions of patients, families, investigators, and clinical trial teams who participated in the development program.

The company plans to work closely with the FDA throughout the review process while preparing for a potential launch if regulatory approval is granted.

Additional Clinical Programs Continue

Beyond the completed Phase 3 DRAGON study, Belite Bio continues to evaluate tinlarebant in other ongoing clinical trials.

The Phase 2/3 DRAGON II study is currently assessing the therapy in adolescent and adult patients with Stargardt disease.

At the same time, the Phase 3 PHOENIX trial is investigating tinlarebant in patients with geographic atrophy associated with advanced dry age-related macular degeneration.

These studies are expected to further expand understanding of tinlarebant's potential across retinal diseases linked to toxic bisretinoid accumulation.

About Belite Bio

Belite Bio is a clinical-stage biotechnology company focused on developing therapies for degenerative retinal diseases and selected metabolic disorders. The company’s research efforts are centered on addressing diseases with significant unmet medical needs, including Stargardt disease type 1 and geographic atrophy.

Tinlarebant remains the company’s lead investigational candidate and represents one of the most advanced programs currently being developed for Stargardt disease.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!